FDA expands approval of Kyprolis to include combination with Darzalex Faspro and dexamethasone.
The expansion of the Kyprolis prescribing information to include Darzalex Faspro plus dexamethasone was supported by the ongoing, Phase 2, non-randomized, open-label, multicenter PLEIADES trial evaluating the clinical benefit of Darzalex Faspro administered in combination with four standard-of-care treatment regimens in patients with multiple myeloma.
Updated data from the PLEIADES study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting, demonstrating that response rates with Kyprolis in combination with Darzalex Faspro and dexamethasone were similar to those in the Phase III CANDOR study (Kyprolis combined with intravenous [IV] Darzalex and dexamethasone [DKd]), which supported the first-ever approval of an anti-CD38 monoclonal antibody in combination with Kyprolis. The PLEIADES study met its primary endpoint, demonstrating an overall response rate of 84.8 percent with Darzalex Faspro-Kd.
Related news and insights
Merck Inc announced that the European Commission has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Biogen and Eisai announced additional details about the Phase IV post-marketing confirmatory study, ENVISION, of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease, including details of the study’s goal for diverse enrollment and primary endpoint.
Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization (CMA) of Pfizer’s Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.